Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

SML1804

Sigma-Aldrich

AM4113

≥98% (HPLC)

Synonyma:

5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C17H12Cl3N3O
Číslo CAS:
Molekulová hmotnost:
380.66
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to brown

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

ClC1=CC(Cl)=C(N2C(C3=CC=C(Cl)C=C3)=C(C)C(C(N)=O)=N2)C=C1

InChI key

BBUKVPCUOHFAQN-UHFFFAOYSA-N

Biochem/physiol Actions

AM4113 is a Cannabinoid CB-1 neutral antagonist.
AM4113 is a Cannabinoid CB-1 neutral antagonist. AM4113 reduced reward and reinstatement of drug-seeking behavior, reducing cue-induced reinstatement in monkeys trained to self-administer cocaine.
AM4113 is a pyrazole-3-carboxamide analog of rimonabant (SR141716A). In rats, it suppresses food-motivated behaviors and food intake, thereby reducing weight gain without inducing nausea. AM4113 has poor oral bioavailability. Therefore, it may not act as an effective appetite suppressant in humans.

hcodes

Hazard Classifications

Aquatic Chronic 4

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Nevidíte správnou verzi?

Potřebujete-li konkrétní verzi, můžete vyhledat daný certifikát podle čísla dávky nebo čísla šarže.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

K S Sink et al.
Pharmacology, biochemistry, and behavior, 91(3), 303-306 (2008-08-16)
Drugs that interfere with cannabinoid CB1 transmission suppress food-motivated behaviors, and may be clinically useful as appetite suppressants. Several CB1 receptor inverse agonists, such as rimonabant and AM251, as well as the CB1 receptor neutral antagonist, AM4113, have been assessed
Sherrica Tai et al.
Psychopharmacology, 232(15), 2751-2761 (2015-03-17)
Previous reports shows rimonabant's inverse properties may be a limiting factor for treating cannabinoid dependence. To overcome this limitation, neutral antagonists were developed, to address mechanisms by which an inverse agonist and neutral antagonist elicit withdrawal. The objective of this
Brian D Kangas et al.
The Journal of pharmacology and experimental therapeutics, 344(3), 561-567 (2013-01-05)
Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. Recent laboratory studies suggest that the effects of CB(1) neutral antagonists differ from those of
T U C Järbe et al.
Pharmacology, biochemistry, and behavior, 91(1), 84-90 (2008-07-22)
We examined open-field effects in rats of the cannabinoid 1 receptor (CB1R) agonist WIN55,212-2 (WIN; 3 mg/kg) and its interaction with the CB1R putative neutral antagonist AM4113 (0.3 to 3 mg/kg). Separate studies examined AM4113 alone (0.3 to 5.6 mg/kg).
Charles W Schindler et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 41(9), 2283-2293 (2016-02-19)
Nicotine, the main psychoactive component of tobacco, and (-)-Δ(9)-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, play major roles in tobacco and marijuana dependence as reinforcers of drug-seeking and drug-taking behavior. Drugs that act as inverse agonists of cannabinoid CB1

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.